Table 1.
Baseline demographic and clinical characteristics of the study population
| Healthy (n=20) | PsO (n=23) | PsA (n=31) | P value | |
|---|---|---|---|---|
| Age, mean±SD (range) | 41.0±9.3 (24–57) | 47.3±12.6 (27–69) | 40.9±13.1 (21–66) | 0.113 |
| Sex | 0.465 | |||
| Female (%) | 9 (45.0) | 12 (52.2) | 11 (35.5) | |
| Male (%) | 11 (55.0) | 11 (47.8) | 20 (64.5) | |
| Race | 0.541* | |||
| Caucasian | 15 (75.0) | 19 (82.6) | 27 (87.1) | |
| Non-Caucasian | 5 (25.0) | 4 (17.4) | 4 (12.9) | |
| Ethnicity | 0.563* | |||
| Hispanic | 4 (20.0) | 4 (17.4) | 9 (29.0) | |
| Non-Hispanic | 16 (80.0) | 19 (82.6) | 22 (71.0) | |
| BSA severity | 0.678* | |||
| Mild (<3% BSA) (%) | N/A | 4 (17.4) | 8 (25.8) | |
| Moderate (3%–10% BSA) (%) | N/A | 10 (43.5) | 9 (29.0) | |
| Severe (>10% BSA) (%) | N/A | 3 (13.0) | 6 (19.4) | |
| Not recorded (%) | N/A | 6 (26.1) | 8 (25.8) | |
| TJC, median (range) | N/A | N/A | 5.5 (0–20)† | N/A |
| SJC, median (range) | N/A | N/A | 2 (0–17)† | N/A |
| Dactilytis | N/A | N/A | 11 (35.5) | N/A |
| Enthesitis | N/A | N/A | 17 (54.9) | N/A |
| Treatment for lesions | 0.431 | |||
| Topical steroids | N/A | 20 | 25 | |
| UV | N/A | 7 | 6 | |
| Intralesional steroids | N/A | 1 | 2 |
Statistical significance calculated using the χ2 test for dichotomous variables and the one-way ANOVA for continuous variables.
*
One or more comparison groups has<5 entries, an assumption that is used in the χ2 test.
†
One subject did not have joint counts recorded.
ANOVA, analysis of variance; BSA, body surface area; N/A, not available; PsA, psoriatic arthritis; PsO, psoriasis; SJC, swollen joint count; TJC, tender joint count; UV, ultraviolet.